PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Go online to PeerView.com/WYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Robust clinical evidence supports effective upfront treatment platforms based on novel multitargeted tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitor therapies, now standard for patients with renal cell carcinoma (RCC). New options across the disease spectrum allow more patients with metastatic, refractory, or high-risk localized disease to benefit. In PeerView’s latest Clinical Consults video, an expert panel will share their insight for effectively integrating different treatment approaches linked to the latest evidence and expand upon real-life experiences and practical guidance. Upon completion of this activity, participants should be better able to: Evaluate evidence on the role of novel and emerging therapeutics, efficacy, and safety for patients with RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging therapeutic approaches, latest evidence, and patient-, disease- and treatment-specific factors; and Integrate evidence-based strategies and best practices to recognize, mitigate, and manage the unique suite of adverse events associated with novel treatment approaches for patients with RCC

Go online to PeerView.com/UHP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the main clinical features and pathophysiologic mechanisms of autoimmune hemolytic anemia (AIHA), as well as appropriate strategies to differentiate cold agglutinin disease from other forms of AIHA in providing optimal care for patients. Upon completion of this activity, participants should be better able to: Recognize the main clinical features and pathophysiologic mechanisms of autoimmune hemolytic anemia (AIHA), and Employ appropriate strategies to differentiate cold agglutinin disease (CAD) from other forms of autoimmune hemolytic anemia (AIHA) to provide optimal care for patients.

Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.

Go online to PeerView.com/ZYP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This educational program exposes learners to the science that supports the use of GnRH antagonists for appropriate patients with advanced prostate cancer and will enhance their ability to select optimal ADT regimens based on CV risk and other clinically-relevant factors, and optimize CV care and outcomes during ADT. Through a collection of short, focused educational modules, learners will combine self-assessment with concise clinical content in an interactive format. An expert GU oncologist presents digestible self-study segments, with a particular focus on CV considerations associated with ADT approaches. Explore topics pertinent to effective management of patients with prostate cancer on ADT regimens in your clinical practice and learn more about the impact of CV considerations and team-based models of care. Upon completion of this activity, participants should be better able to: Differentiate between GnRH analogues (agonists or antagonists) for patients with advanced prostate cancer with respect to their mechanism of action, clinical effects, cardiovascular (CV) safety, and other attributes; Select patients with advanced prostate cancer who may benefit from treatment with a GnRH antagonist based on CV risk, comorbidities, patient preferences (eg, regarding dosing and/or administration route), and other individualized factors; and Collaborate with multidisciplinary and interprofessional care colleagues to appropriately assess and manage CV risk in patients with advanced prostate cancer who require ADT.

Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

Go online to PeerView.com/QCN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hyperlipidemia discusses evidence-based strategies for diagnosing and individualizing treatment plans with PCSK9-targeting agents to improve patient outcomes. Upon completion of this activity, participants should be better able to: Perform a diagnostic evaluation based on current clinical guidelines for the treatment of hyperlipidemia; Assess the mechanisms of action, efficacy, and safety of PCSK9-targeting agents designed to further reduce lipid levels in patients with hyperlipidemia; Identify patients who may benefit from treatment with PCSK9-targeting therapies; and Recognize the role of multidisciplinary collaboration and patient education to optimize outcomes in patients with hyperlipidemia.

Go online to PeerView.com/JKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert in hypersomnolence discusses the diagnosis, classification, and treatment of narcolepsy and idiopathic hypersomnia. Using real-life cases as examples, the latest data and guidelines are reviewed in juxtaposition with the patients’ stories. Upon completion of this activity, participants should be better able to: Describe how delayed diagnosis of narcolepsy or idiopathic hypersomnia (IH) exacerbates the multifaceted burdens associated with both conditions; Apply International Classification of Sleep Disorders criteria to assess patients who present with excessive daytime sleepiness (EDS) or other signs or symptoms suggesting narcolepsy or IH; and Individualize treatment of narcolepsy and IH, based on the latest clinical evidence and guidelines; patient needs, preferences, and comorbidities; and considerations that affect adherence.